Silo Pharma Inc (NASDAQ:SILO) stock is surging on Thursday, with a session volume of 88 million compared to an average volume of 3.2 million, as per data from Benzinga Pro.
The company entered into a Device and CMC Development Master Plan with Resyca BV, a medical technology provider.
Resyca is a joint venture between Bespak Group and Medspray Pharma BV, which manufactures the formulation-specific microchip-based spray system chosen by Silo for its lead candidate SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).
“The patented nasal spray system uses cutting-edge nose-to-brain drug dispersion, a delivery method that transports the ...